Preclinical investigation in FAAH inhibition as a neuroprotective therapy for frontotemporal dementia using TDP-43 transgenic male mice

[1]  J. Fernández-Ruiz,et al.  Preclinical investigation of β-caryophyllene as a therapeutic agent in an experimental murine model of Dravet syndrome , 2021, Neuropharmacology.

[2]  E. Finger,et al.  Pharmacotherapy for Neuropsychiatric Symptoms in Frontotemporal Dementia , 2021, CNS Drugs.

[3]  P. Zhao,et al.  Neuroprotective Effects of VEGF-A Nanofiber Membrane and FAAH Inhibitor URB597 Against Oxygen–Glucose Deprivation-Induced Ischemic Neuronal Injury , 2021, International journal of nanomedicine.

[4]  J. Lanciego,et al.  Cannabinoid receptor CB2 ablation protects against TAU induced neurodegeneration , 2021, Acta neuropathologica communications.

[5]  F. Hirth,et al.  Triad of TDP43 control in neurodegeneration: autoregulation, localization and aggregation , 2021, Nature Reviews Neuroscience.

[6]  J. Hai,et al.  Preservation of spatial memory and neuroprotection by the fatty acid amide hydrolase inhibitor URB597 in a rat model of vascular dementia , 2021, Annals of translational medicine.

[7]  J. Fernández-Ruiz,et al.  Targeting the CB2 receptor and other endocannabinoid elements to delay disease progression in amyotrophic lateral sclerosis , 2021, British journal of pharmacology.

[8]  F. Piscitelli,et al.  Cannabinoids: a class of unique natural products with unique pharmacology , 2021, Rendiconti Lincei. Scienze Fisiche e Naturali.

[9]  G. Gopalakrishna,et al.  Cannabinoids in the management of frontotemporal dementia: a case series. , 2020, Neurodegenerative disease management.

[10]  M. Aschner,et al.  URB597 Prevents the Short-Term Excitotoxic Cell Damage in Rat Cortical Slices: Role of Cannabinoid 1 Receptors , 2020, Neurotoxicity Research.

[11]  O. Piguet,et al.  Frontotemporal dementias: main syndromes and underlying brain changes. , 2020, Current opinion in neurology.

[12]  A. Lichtman,et al.  Protective effects of N-oleoylglycine in a mouse model of mild traumatic brain injury. , 2020, ACS chemical neuroscience.

[13]  T. Bisogno,et al.  Cannabinoids and the expanded endocannabinoid system in neurological disorders , 2019, Nature Reviews Neurology.

[14]  J. Hai,et al.  URB597 protects against NLRP3 inflammasome activation by inhibiting autophagy dysfunction in a rat model of chronic cerebral hypoperfusion , 2019, Journal of Neuroinflammation.

[15]  T. Bisogno,et al.  Different Routes to Inhibit Fatty Acid Amide Hydrolase: Do All Roads Lead to the Same Place? , 2019, International journal of molecular sciences.

[16]  F. Papaleo,et al.  Acute Administration of URB597 Fatty Acid Amide Hydrolase Inhibitor Prevents Attentional Impairments by Distractors in Adolescent Mice , 2019, Front. Pharmacol..

[17]  W. Zou,et al.  The Appropriate Marker for Astrocytes: Comparing the Distribution and Expression of Three Astrocytic Markers in Different Mouse Cerebral Regions , 2019, BioMed research international.

[18]  J. Rohrer,et al.  An update on genetic frontotemporal dementia , 2019, Journal of Neurology.

[19]  J. Fernández-Ruiz,et al.  Targeting glial cannabinoid CB2 receptors to delay the progression of the pathological phenotype in TDP‐43 (A315T) transgenic mice, a model of amyotrophic lateral sclerosis , 2019, British journal of pharmacology.

[20]  N. Jadavji,et al.  Assessing Spatial Working Memory Using the Spontaneous Alternation Y-maze Test in Aged Male Mice. , 2019, Bio-protocol.

[21]  B. Borroni,et al.  Review: Molecular pathology of frontotemporal lobar degenerations , 2019, Neuropathology and applied neurobiology.

[22]  F. Pavón,et al.  Pharmacological blockade of fatty acid amide hydrolase (FAAH) by URB597 improves memory and changes the phenotype of hippocampal microglia despite ethanol exposure , 2018, Biochemical pharmacology.

[23]  J. Fernández-Ruiz.  The biomedical challenge of neurodegenerative disorders: an opportunity for cannabinoid‐based therapies to improve on the poor current therapeutic outcomes , 2018, British journal of pharmacology.

[24]  H. Morrison,et al.  Quantifying Microglia Morphology from Photomicrographs of Immunohistochemistry Prepared Tissue Using ImageJ , 2018, Journal of visualized experiments : JoVE.

[25]  A. Santamaría,et al.  The Pharmacological Inhibition of Fatty Acid Amide Hydrolase Prevents Excitotoxic Damage in the Rat Striatum: Possible Involvement of CB1 Receptors Regulation , 2018, Molecular Neurobiology.

[26]  A. Santamaría,et al.  The Pharmacological Inhibition of Fatty Acid Amide Hydrolase Prevents Excitotoxic Damage in the Rat Striatum: Possible Involvement of CB1 Receptors Regulation , 2018, Molecular Neurobiology.

[27]  M. T. Grande,et al.  Cannabinoid CB2 receptors in the mouse brain: relevance for Alzheimer’s disease , 2018, Journal of neuroinflammation.

[28]  Nick C Fox,et al.  Pathological correlates of white matter hyperintensities in a case of progranulin mutation associated frontotemporal dementia , 2018, Neurocase.

[29]  V. Kitchigina,et al.  Fatty acid amide hydrolase inhibitor URB597 may protect against kainic acid–induced damage to hippocampal neurons: Dependence on the degree of injury , 2017, Epilepsy Research.

[30]  R. López-González,et al.  Dysregulated molecular pathways in amyotrophic lateral sclerosis–frontotemporal dementia spectrum disorder , 2017, The EMBO journal.

[31]  J. García-Verdugo,et al.  Amyotrophic lateral sclerosis modifies progenitor neural proliferation in adult classic neurogenic brain niches , 2017, BMC Neurology.

[32]  Lindsay M Lueptow,et al.  Novel Object Recognition Test for the Investigation of Learning and Memory in Mice. , 2017, Journal of visualized experiments : JoVE.

[33]  F. Elahi,et al.  A clinicopathological approach to the diagnosis of dementia , 2017, Nature Reviews Neurology.

[34]  M. Delgado,et al.  Effects of a Sativex-Like Combination of Phytocannabinoids on Disease Progression in R6/2 Mice, an Experimental Model of Huntington’s Disease , 2017, International journal of molecular sciences.

[35]  L. Fan,et al.  Dysregulation of neurogenesis by neuroinflammation: key differences in neurodevelopmental and neurological disorders , 2017, Neural regeneration research.

[36]  C. Fanali,et al.  Lifelong imbalanced LA/ALA intake impairs emotional and cognitive behavior via changes in brain endocannabinoid system , 2017, Journal of Lipid Research.

[37]  P. Chavatte,et al.  Therapeutic Potential of Fatty Acid Amide Hydrolase, Monoacylglycerol Lipase, and N-Acylethanolamine Acid Amidase Inhibitors. , 2017, Journal of medicinal chemistry.

[38]  T. Lynch,et al.  Genetics of Frontotemporal Dementia , 2016, Current Neurology and Neuroscience Reports.

[39]  H. Ryu,et al.  Astrocytes and Microglia as Non-cell Autonomous Players in the Pathogenesis of ALS , 2016, Experimental Neurobiology.

[40]  Knut Engedal,et al.  Frontotemporal Dementia , 2016, Journal of geriatric psychiatry and neurology.

[41]  J. Fernández-Ruiz,et al.  Targeting the cannabinoid CB2 receptor to attenuate the progression of motor deficits in LRRK2-transgenic mice. , 2016, Pharmacological research.

[42]  Peter Veselcic,et al.  Mutant Tau knock-in mice display frontotemporal dementia relevant behaviour and histopathology , 2016, Neurobiology of Disease.

[43]  S. Petrosino,et al.  Endocannabinoids and endocannabinoid-related mediators: Targets, metabolism and role in neurological disorders. , 2016, Progress in lipid research.

[44]  Torfi Sigurdsson,et al.  Hippocampal-Prefrontal Interactions in Cognition, Behavior and Psychiatric Disease , 2016, Front. Syst. Neurosci..

[45]  Ann M. Graybiel,et al.  Neurobiology of rodent self-grooming and its value for translational neuroscience , 2015, Nature Reviews Neuroscience.

[46]  Conor Liston,et al.  Projections from neocortex mediate top-down control of memory retrieval , 2015, Nature.

[47]  V. Marzo,et al.  Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice: relevance for a neuroprotective therapy in TDP-43-related disorders , 2015, Journal of Neuroimmune Pharmacology.

[48]  D. Na,et al.  Postmorbid learning of saxophone playing in a patient with frontotemporal dementia , 2015, Neurocase.

[49]  S. Rollinson,et al.  Patterns of microglial cell activation in frontotemporal lobar degeneration , 2014, Neuropathology and applied neurobiology.

[50]  A. Kurz,et al.  What is frontotemporal dementia? , 2014, Maturitas.

[51]  J. Fernández-Ruiz,et al.  Changes in Endocannabinoid Receptors and Enzymes in the Spinal Cord of SOD1G93A Transgenic Mice and Evaluation of a Sativex®‐like Combination of Phytocannabinoids: Interest for Future Therapies in Amyotrophic Lateral Sclerosis , 2014, CNS neuroscience & therapeutics.

[52]  V. Di Marzo,et al.  Prostamide F2α receptor antagonism combined with inhibition of FAAH may block the pro‐inflammatory mediators formed following selective FAAH inhibition , 2014, British journal of pharmacology.

[53]  D. Pfaff,et al.  CB1 receptor signaling regulates social anxiety and memory , 2013, Genes, brain, and behavior.

[54]  D. Geschwind,et al.  TDP-43 frontotemporal lobar degeneration and autoimmune disease , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[55]  Robert V Farese,et al.  Dissociation of Frontotemporal Dementia–Related Deficits and Neuroinflammation in Progranulin Haploinsufficient Mice , 2013, The Journal of Neuroscience.

[56]  Nick C Fox,et al.  Longitudinal neuroimaging and neuropsychological profiles of frontotemporal dementia with C9ORF72 expansions , 2012, Alzheimer's Research & Therapy.

[57]  John L. Robinson,et al.  Pattern of ubiquilin pathology in ALS and FTLD indicates presence of C9ORF72 hexanucleotide expansion , 2012, Acta Neuropathologica.

[58]  A. Lichtman,et al.  Discovery of Prostamide F2α and Its Role in Inflammatory Pain and Dorsal Horn Nociceptive Neuron Hyperexcitability , 2012, PloS one.

[59]  N. Cairns,et al.  Core features of frontotemporal dementia recapitulated in progranulin knockout mice , 2012, Neurobiology of Disease.

[60]  Adem Can,et al.  The tail suspension test. , 2011, Journal of visualized experiments : JoVE.

[61]  Marta Coelho Antunes,et al.  The novel object recognition memory: neurobiology, test procedure, and its modifications , 2011, Cognitive Processing.

[62]  M. Antunes,et al.  The novel object recognition memory: neurobiology, test procedure, and its modifications , 2011, Cognitive Processing.

[63]  Nick C Fox,et al.  Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. , 2011, Brain : a journal of neurology.

[64]  J. Trojanowski,et al.  A harmonized classification system for FTLD-TDP pathology , 2011, Acta Neuropathologica.

[65]  C. Troakes,et al.  Ubiquitinated, p62 immunopositive cerebellar cortical neuronal inclusions are evident across the spectrum of TDP‐43 proteinopathies but are only rarely additionally immunopositive for phosphorylation‐dependent TDP‐43 , 2011, Neuropathology : official journal of the Japanese Society of Neuropathology.

[66]  Nick C Fox,et al.  Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[67]  Kuan-Hung Cho,et al.  Ar Ticle Elevated Expression of Tdp-43 in the Forebrain of Mice Is Sufficient to Cause Neurological and Pathological Phenotypes Mimicking Ftld-u , 2022 .

[68]  C. Lord,et al.  Behavioural phenotyping assays for mouse models of autism , 2010, Nature Reviews Neuroscience.

[69]  H. Hansen.  Palmitoylethanolamide and other anandamide congeners. Proposed role in the diseased brain , 2010, Experimental Neurology.

[70]  R. Vertes,et al.  Anatomical analysis of afferent projections to the medial prefrontal cortex in the rat , 2007, Brain Structure and Function.

[71]  A. Walf,et al.  The use of the elevated plus maze as an assay of anxiety-related behavior in rodents , 2007, Nature Protocols.

[72]  C. Vorhees,et al.  Morris water maze: procedures for assessing spatial and related forms of learning and memory , 2006, Nature Protocols.

[73]  L. Greensmith,et al.  Increasing cannabinoid levels by pharmacological and genetic manipulation delays disease progression in SOD1 mice , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[74]  Daniele Piomelli,et al.  Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). , 2006, CNS drug reviews.

[75]  B. Hyman,et al.  Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function , 2005, Science.

[76]  J. W. Aldridge,et al.  Sequential super-stereotypy of an instinctive fixed action pattern in hyper-dopaminergic mutant mice: a model of obsessive compulsive disorder and Tourette's , 2005, BMC Biology.

[77]  R. Hughes.  The value of spontaneous alternation behavior (SAB) as a test of retention in pharmacological investigations of memory , 2004, Neuroscience & Biobehavioral Reviews.

[78]  K. Blennow,et al.  Increased intrathecal inflammatory activity in frontotemporal dementia: pathophysiological implications , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[79]  T. Jay,et al.  Working memory deficits in adult rats after prenatal disruption of neurogenesis , 2004, Behavioural pharmacology.

[80]  M. Kliot,et al.  Endocannabinoids accumulate in spinal cord of SOD1G93A transgenic mice , 2004, Journal of neurochemistry.

[81]  M. Elphick,et al.  Comparative analysis of fatty acid amide hydrolase and cb1 cannabinoid receptor expression in the mouse brain: evidence of a widespread role for fatty acid amide hydrolase in regulation of endocannabinoid signaling , 2003, Neuroscience.

[82]  T. Hashikawa,et al.  Tau filament formation and associative memory deficit in aged mice expressing mutant (R406W) human tau , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[83]  M. Elphick,et al.  A new perspective on cannabinoid signalling: complimentary localization of fatty acid amide hydrolase and the CB1 receptor in rat brain. , 1998, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[84]  L. Gustafson,et al.  Frontal lobe degeneration of non-Alzheimer type. II. Clinical picture and differential diagnosis. , 1987, Archives of gerontology and geriatrics.

[85]  R. Morris.  Developments of a water-maze procedure for studying spatial learning in the rat , 1984, Journal of Neuroscience Methods.

[86]  M. Mena,et al.  Natural cannabinoids improve dopamine neurotransmission and tau and amyloid pathology in a mouse model of tauopathy. , 2013, Journal of Alzheimer's disease : JAD.

[87]  S. Cerdán,et al.  Systematic evaluation of magnetic resonance imaging and spectroscopy techniques for imaging a transgenic model of Alzheimer's disease (AβPP/PS1). , 2012, Journal of Alzheimer's disease : JAD.

[88]  B. Thierry,et al.  The tail suspension test: A new method for screening antidepressants in mice , 2004, Psychopharmacology.

[89]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..